GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Ranbaxy Acquires New Responsibilities and About $100M through Expanded Alliance with GSK

  • Ranbaxy Laboratories gained additional development responsibilities and further financial opportunities through the expansion of its alliance with GlaxoSmithKline.

    Under the original 2003 agreement, Ranbaxy conducted the optimization chemistry required to progress drug leads to the stage of candidate selection. Under the new multiyear R&D agreement, Ranbaxy will advance leads beyond candidate selection to completion of clinical proof of concept. GSK thereafter will conduct further development for each program and take resulting products through the regulatory approval process to final commercialization.

    Ranbaxy could receive over $100 million in milestone payments and up to double-digit royalties on worldwide net sales. Ranbaxy will retain the right to co-commercialize the products in India. The new milestones and royalties will apply to the two programs ongoing at Ranbaxy, under the original agreement with GSK, as well as to future drug discovery programs.

    GSK says the expanded alliance could lead to potential work in a range of therapeutics, including anti-infectives and metabolic, respiratory, and oncology products.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »